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screening rateMethods: Women not having Pap smear screening for > 5 years were invited to participate in
this study. Invitation letters and educational brochures were mailed to 4% of randomly selected
eligible women from Taoyuan City, Taiwan, and responders received an HPV self-sampling kit.
Those with HPV-positive results were recalled for a Pap smear and colposcopy.
Results: Between March 2010 and June 2012, 10,693 women were invited, 354 responded
(3.3%), and 282 (2.6%) gave valid informed consent, answered the questionnaire, and submit-
ted HPV samples. The median age of enrolled women was 48.1 years. Forty-seven women
(16.7%) had a positive HPV test, and 14 women accepted further survey to find two CIN2þ.
Another two cases of CIN2þ were identified from a national registry database. The cost of
direct mailing self-samplers was less than that done on request (from NT$434,866 to
NT$164,229, response rate of 5% to 15%, respectively, versus NT$683,957 for detecting 1
CIN2þ). Reasons for not attending screening included lack of time, embarrassment, assumed
low risk, fear of positive results, and perceived potential pain. Among the responders, 90.8%
found the method acceptable.
Conclusion: Our study indicated that different approaches (e.g., direct mailing self-samplers
to under-users and/or various educational interventions) must be explored to improve
coverage in populations with culture characteristics similar to Taiwan.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Under-utilization of Papanicolaou (Pap) smear causes a gap
in the prevention of cervical neoplasms in many countries.
Around 30% of females aged > 30 years did not undergo a
Pap smear in the past 5 years, which sets a caveat in the
prevention of cervical cancer in Taiwan.1 In the countries
with long sustained Pap smear programs, most invasive
cervical cancers (between 60% and 80%) are found in women
who have not had a Pap test within the past 5 years.2
Whether this under-screening rate has been due to sexual
discrimination, social, cultural, or medical inconvenience
has yet to be determined by population-based studies.
Human papillomavirus (HPV) is the etiology of high-
grade cervical intraepithelial neoplasm (CIN) and cervical
cancer.3 Pap smear and HPV co-tests in women aged 
30 years are recommended every 5 years as primary
cervical screening in developed countries. A single
“screen-and-treat” visual inspection with acetic acid
might be reasonable in areas with very limited re-
sources.4,5 However, a report from The Netherlands
showed that primary HPV screening was not cost-
effective for young women (a combination of primary
cytology screening for women < 33 years of age), while
HPV screening for older women can be more cost-
effective with primary HPV screening.6
HPV testing using self-sampling specimens for cervical
screening have been studied by many investigators.7e9 A
recent meta-analysis also confirmed that sensitivity of self-
sampling vaginal specimens is generally comparable to the
physician-collected cervical samples by polymerase chain
reaction (PCR)-based methods, although self-sampling spec-
imens might be slightly inferior by signal-based methods.9 A
randomized study from The Netherlands of 2830 women not
responding to regular national screening reminders revealed
that they were more willing to do self-sampling HPV testing
(34.2%) than to accept a recalled cytology (17.6%).10 Anotherstudy from Sweden reported a 39.1% response rate for self-
sampling HPV testing done at home for women not
attending organized screening for 6 years.11
The current study aimed to investigate: (1) if a self-
sampling vaginal swab for HPV testing would be acceptable
to women without a Pap smear for > 5 years and (2) the
cost of finding one CIN2 or a more severe CIN2þ in a pop-
ulation with low screening rates. The study results might
answer whether a self-sampling HPV test could be imple-
mented among under-users of Pap smear, and could provide
a national policy reference for the strategy of promoting
primary prevention of cervical cancer.Methods
Eligibility criteria and patient recruitment
This prospective study was approved by the Institutional
Review Board of Chang Gung Memorial Hospital, Taoyuan,
Taiwan (IRB 97-2300A3). A list of women residing in Taoyuan
City, Taiwan, and not having Pap smear screening in the
past 5 years (n Z 259,162) was obtained from the Depart-
ment of Public Health, Taoyuan City government. We
planned to recruit 1500 participants and 1200 valid speci-
mens. To achieve this, we mailed a study invitation, a copy
of the informed consent, and a health brochure to 4% of
randomly selected women from the list, and assumed that
15% of the receivers would mail back their letter of intent.
The responders would receive a second letter enclosing an
HPV self-sampling kit and a copy of a post-test question-
naire. Our HPV self-sampling kit included a self-sampling
brush and a copy of instructions (Iron Will Biomedical
Technology, New Taipei, Taiwan). They were instructed to
perform self-sampling by inserting the swab into the vagina
w5e8 cm deep, rotating it 360, putting it into the test
tube containing preserving medium, and mailing it back to
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envelope.
Women issuing informed consent and answering the
questionnaire were eligible for analysis of factors relating
to under-utilization of Pap smear, while those having the
former two, but absent vaginal samples, were excluded
from further analysis. All participants gave written
permission to obtain their 15-year health data regarding
Pap smear frequency, cytological, and pathologic reports
from the Taiwanese national registry database. Women
with positive HPV results would be notified to come to
Chang Gung Memorial Hospital for a colposcopy, Pap smear,
and/or cervical biopsy.
DNA extraction and SPF1/GP6D PCR
DNA was extracted according to the protocol for isolation of
total DNA from cultured animal cells (Qiagen Inc., Valencia,
CA, USA) and as described previously.12e14 In all cases,
100 ng was used for each PCR,14 and the SPF1/GP6þ
consensus primers were used to amplify a fragment of
approximately 184 bp in the L1 open reading frame, as
previously described.12e14
HPV genotyping by Easychip HPV Blot and E6 type-
specific PCR
Fifteen microliters of the resulting amplimers were hy-
bridized with an Easychip HPV Blot (King Car, I-Lan, Taiwan)
membrane. Thirty-eight types of HPV [6, 11, 16, 18, 26, 31,
32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 66, 67, 68, 69, 70, 71 (CP8061), 72, 74, 81
(CP8304), 82 (MM4), 83 (MM7), 84 (MM8), and L1AE5] were
capable of detection. The hybridization and detection
procedures have been reported previously.12e14 The E6
type-specific PCRs were performed in order to validate the
types of multiple infections.
HPV types were divided into two groups (low-risk and
high-risk). The leading 14 HPV types (HPV-16, -18, -58, -33,
-52, -39, -45, -31, -51, -70, -56, -59, -35, and -53) linked to
cervical cancer in Taiwanese women15 were grouped
together in the high-risk group, while the remaining 24 HPV
types were considered low-risk.
Data analysis
Descriptive analyses to assess the prevalence rate of HPV
infection according to host characteristics (age, education,
economic status, knowledge of cervical cancer/HPV, and
attitude toward cervical screening). The cost analysis was
based on finding CIN2þ over a 3-year period. Odds ratio
(OR) of finding CIN2þ by HPV results with a 95% confidence
interval (CI) was calculated using information from the
national registry database obtained from the Health Pro-
motion Administration, Taiwan. We calculated the utiliza-
tion of cervical screening with 5-year intervals up to 15
years, and the occurrence of CIN2þ in participants or
women receiving invitations as compared to those not
invited. The cost calculation was based on actual direct
cost (mail, sampling kits, HPV testing, Pap smears, col-
poscopy, and cervical conization). All calculations wereperformed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA) and
STATA 9.0 (StataCorp LP, College Station, TX, USA).
Results
Between March 2010 and June 2012, a total of 10,693
women were invited. The original study design is repre-
sented in Figure 1. Of these, 354 (3.3%) responded and 352
submitted post-educational questionnaires and informed
consent, but only 282 (2.6%) returned valid informed con-
sent, a completed questionnaire, and HPV-test samples.
Seventy women gave informed consent, but did not return
HPV-test specimens. The median age of enrolled women
was 48.1 years (range, 35.2e79.7 years). Among the 282
women with a valid HPV sample, 47 (16.7%) had positive
results.
HPV, Pap, and colposcopy results
Fourteen of the 47 women with HPV-positive results (29.8%)
came to the hospital for further investigation. All 14
received colposcopy, while nine also received a Pap smear.
The overall abnormal cytological diagnosis [atypical squa-
mous cells of undetermined significance or worse
(ASCUSþ)] rates in women receiving Pap were 33.3% (3/9).
Of the 14 women who received a colposcopy, three cases
with histology-proven CIN (1 with CIN 1 and 2 with CIN 2)
were found. The findings/HPV types of these 14 women are
provided in Table 1. Among the 47 women having positive
HPV tests, 78.7% harbored a single type of infection, and
21.3% had multiple types, with the three most common
types being HPV70, HPV52, and HPV71.
Analyses using the national registry database
Thirty-three of the 47 HPV-positive women were unavai-
lable to attend our next step. According to the national
registry database, 40 (57.1%) of the 70 women without HPV-
test specimens, 23 (70.0%) of the 33 unavailable HPV-
positive women, and 136 (57.9%) of the 235 HPV-negative
women accepted Pap smear or cervical biopsy between
August 2010 and December 2013. This study has clearly
impacted these participating under-users, regardless of
HPV results. Between March 2010 and December 2013, one
CIN2þ occurred in each of the unavailable HPV-positive and
HPV-negative groups, but none occurred in those without
HPV. With a median follow-up of 31.4 months, the rates of
finding CIN2þ by HPV-positivity calculated using national
registry database were 6.4% (3/47) for HPV-positive
(HPV16, HPV52, and HPV58) and 0.4% (1/235) for HPV-
negative women. The OR of HPV-positive to HPV-negative
was 15.96 (95% CI, 1.62e156.9; Fisher’s exact test;
p Z 0.015).
Reasons of Pap smear under-utilization
For the responders (n Z 354), there were no differences
between women providing valid informed consent,
completing the questionnaire, and providing HPV-sample
specimens (n Z 282) and those who did not (n Z 70) in
Figure 1 Flowchart describing this study. CIN 1 Z cervical intraepithelial neoplasia Grade 1; CIN2þ Z cervical intraepithelial
neoplasia Grade 2 or worse.
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come, or family economic status (Table S1). The reasons for
their not attending screening included embarrassment
(36.4%), lack of time (35.8%), forgetting (25.9%), assuming
they were at low risk (24.4%), fear of a positive result
(13.1%) and perceived potential pain (10.8%; Table 2).
Knowledge and beliefs about cervical cancer and
HPV
Most of the responders (92.7%) knew that a Pap smear is a
simple and convenient method used to screen cervical
cancer, and that further evaluation is necessary if the Pap
smear result is abnormal (98.0%). A majority of them
(88.9%) knew that early HPV testing could help to screen for
cervical neoplastic lesions. Menopausal womenmisunderstanding about not needing a Pap smear was not
prevalent (12.8%). Among our responders, 33.5% did not
know that most invasive cervical cancers developed from
pre-invasive lesions, while 79.4% knew that HPV infection is
a sexually transmitted disease (Table 3).
Sources of screening information and knowledge of
cervical neoplasms
Our attendants learned about screening and gained
knowledge of the disease from television (51.4%), news-
papers and magazines (31.3%), and radio (18.5%), while
only 14.5% of them learned from internet websites. They
received medical information from hospital staff (57.4%),
public-health nurses (49.1%), health education brochures
(32.7%), and relatives and friends (16.5%; Table 4).
Table 1 Demographics, colposcopy, and cytology/pa-
thology findings of HPV-positive women who received
further investigations.
Case Age
(y)
Colposcopy Pap smear Pathology HPV
type
1 52 Unsatisfactory NA NA HPV-71
2 63 CIN2/3 NA CIN 3 HPV-58
3 57 CIN2/3 CIN 3 CIN 3 HPV-52
4 41 No dysplasia ASCUS NA HPV-44
5 41 No dysplasia Normal NA HPV-62
6 43 No dysplasia Normal NA HPV-71
7 50 No dysplasia Normal NA HPV-42
8 41 No dysplasia Normal NA HPV-51
9 46 No dysplasia Normal NA HPV-44
10 56 No dysplasia NA NA HPV-70
11 49 No dysplasia NA NA HPV-84
12 50 No dysplasia NA NA HPV-70
13 56 No dysplasia Inflammation NA HPV-70
14 46 No dysplasia ASCUS CIN 1 HPV-52
ASCUS Z atypical squamous cell of undetermined significance;
CIN 1 Z cervical intraepithelial neoplasia Grade 1; CIN 2/
3 Z cervical intraepithelial neoplasia Grade 2 or 3;
HPV Z human papillomavirus; NA Z not applicable.
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Of all responders, 90.8% found self-obtained HPV testing
convenient and acceptable, with 87.2% willing to choose
the self-obtained method in the future, and 88.3% willing to
recommend this test to other people. Post-sampling vaginal
spotting, increased vaginal discharge, and lower-abdominal
discomfort occurred in 10.3% of respondents, with no spe-
cial complaint from 87.9%. A total of 65.2% of responders
thought the HPV self-obtained test gave them resolution for
the unwillingness to attend Pap smear screening (Table 5).Cost analysis
The cost of the project, including mailing, HPV kits, HPV
testing, Pap smear, colposcopy with/without biopsy,
personnel, and consumables came to NT $2,518,921. If we
count all four cases of CIN2þ from the responders (nZ 354)Table 2 Reasons for non-attendance of cervical screening
(n Z 352).
Reasonsa n %
Lack of time 126 35.8
Transport 16 4.5
Fear of positive result 46 13.1
Embarrassed 128 36.4
Perceived potential pain 38 10.8
Feeling of low risk 86 24.4
Forgetting 91 25.9
Others 29 8.2
a More than one reason could be chosen.as benefits of the study impact, the cost of detecting one
CIN2þ case was approximately NT $683,957 (Table S2).Discussion
Previous studies suggested that the sensitivities of HPV
testing were comparable between self-sampling and
clinician-collected samples.7e11 Therefore, we offered the
self-sampling HPV-testing option, as well as health infor-
mation on cervical cancer and HPV with educational bro-
chures, to the under-users of Pap smear in the neighboring
community in the same mailing. Unfortunately, only 3.3% of
the 10,693 women responded. Forty-seven of the 282
(16.7%) women had positive HPV results, and 14 of the 47
(29.8%) received colposcopy/cytology. The HPV-positive
rate tended to be higher among Pap under-users in other
studies,16e18 and in the current study as compared with our
previous population-based study from Taoyuan County (now
Taoyuan City), Taiwan, which found that the HPV preva-
lence rate was 11% among women aged 30e94.19
Our questionnaire revealed that the reasons for not
attending screening included lack of time, embarrassment,
feeling at low risk, fear of positive results, and perceived
potential pain, which could be resolved by appropriate
education and a convenient test. Our attendants learned
about screening and gained knowledge of the disease from
television (51.4%) and newspapers and magazines (31.3%),
while only 14.5% of them learned from internet websites,
which is a source of information that should be considered
in promoting increased coverage rates. Of the full re-
sponders, 90.8% found self-obtained HPV testing conve-
nient and acceptable, with 87.2% willing to choose the self-
obtained method in the future, and 88.3% willing to
recommend this test to other people.
Two CIN2þ women were detected among the 14 women
who underwent further colposcopy/cytology. Another two
were identified from the national registry database, making
the rates of finding CIN2þ by HPV-positivity 6.4% (3/47) for
HPV-positive and 0.4% (1/253) for HPV-negative women,
with a median follow-up of 31.4 months. The OR was 15.96
for HPV-positive women (95% CI, 1.62e156.9; Fisher’s exact
test; p Z 0.015). Except for detecting CIN lesions, the
current study changed those under-users who responded,
because 57.9e70% of responders accepted Pap smear or
cervical biopsy in the following 9 months after enrolment,
regardless of their HPV results.
Similar trials of inviting Pap-non-attendants to perform
self-sampling HPV tests by mail obtained higher response
rates as compared to standard recalls for cytology in En-
gland (10.2% vs. 4.5%) and in The Netherlands (30.8% vs.
6.5%).16,17 In an Italian randomized trial, the response rate
among those directly receiving self-sampling kits was bet-
ter than those either receiving the self-sampling kit on
request, or merely recalled to do a Pap smear (19.6% vs.
8.7% vs. 3.9%).18 The cost of detecting one CIN2þ case in
the current study was approximately NT $683,957, with
mailing HPV kits on request (Table S2). If the alternative
strategy of mailing HPV kits to all under-users could result
in a response rate of 5e15%, and post-intervention follow-
up behavior led to results similar to those observed in this
study, the expected cost (15%, NT $164,229; 10%, NT
Table 3 Knowledge and beliefs about cervical cancer and human papillomavirus (n Z 352).
Questions (standard answer) Answers
n Right (%) Wrong or do
not know (%)
The purpose of Pap smear is to find out early cancer & give therapy early to increase
the cure rate of disease (True)
342 98.5 1.5
The further evaluation is necessary if the Pap smear result is abnormal (True) 345 98.0 2.0
Pap smear is a simple & convenient method to screen cervical cancer (True) 342 92.7 7.3
Pap smear plus HPV test could increase the detecting rate of cervical cancer or its
precursors (True)
343 91.0 9.0
HPV test could help to early screen the cervical neoplastic lesions (True) 342 88.9 11.1
Women with more sexual partner are more easily getting cervical cancer (True) 343 87.8 12.2
All women have risk of HPV infection after sexual debut (True) 342 88.0 12.0
Cervical carcinogenesis is closely related to HPV (True) 341 87.4 12.6
Menopausal women no longer need Pap smear (False) 345 87.2 12.8
Genital HPV is mostly through sexual transmission (True) 340 79.4 20.6
The national insurance provides a yearly Pap smear for women aged 30 years or older (True) 344 78.2 21.8
Cervical cancer a family inherited disease (True) 340 69.4 30.6
Better to avoid intercourse the night before Pap smear (True) 345 69.3 30.7
Most of the invasive cervical cancers developed from pre-invasive lesions (True) 337 66.5 33.5
HPV testing can use self-collected specimens, but not for Pap smear (True) 341 56.0 44.0
Pap smear is the only way of screening for cervical cancer (False) 341 36.4 63.6
HPV Z human papillomavirus.
1094 H.-H. Chou et al.$291,401; 5%, NT $434,866) for detecting one CIN2þ would
be lower than that seen by undergoing the test on request
(Tables S3eS5).
The American Cancer Society, American Society for
Colposcopy and Cervical Pathology, and American Society
for Clinical Pathology consensus guidelines recommended
cervical cytology at 3-year intervals for women aged 21e29
years, and HPV and cytology co-testing every 5 years, or
cytology alone every 3 years in women aged 30e65 years.20
In a long-term community-based study of Taiwanese women
aged 30e65 years (n Z 11,923) with clinician sampled co-
tests, the 16-year cumulative risk of cervical cancer in
HPV-negative women was 0.26% as compared to 13.5% in
HPV16-positive women, and 10.3% in HPV58-positive
women at baseline.21 A recently published pooled analysis
of four randomized trials (n Z 176,464) from European
countries showed that HPV-based screening was better than
cytology-based screening at preventing invasive cervicalTable 4 Sources of information about screening and
knowledge of cervical neoplasms (n Z 352).
Sourcea n %
Hospital 202 57.4
Television 181 51.4
Public health nurse 173 49.1
Health educational brochure 115 32.7
Newspapers & magazines 110 31.3
Relatives & friends 58 16.5
Radio 65 18.5
Internet 51 14.5
Others 1 0.3
a More than one source could be chosen.cancer, with benefits not significant at 2.5 years, but very
significant at 5.5 years.22 HPV-based testing for primary
cervical screening from age 30 years at an interval of 5
years is the world trend.5
The nationwide coverage rate remains a key challenge
to implementing any screening program. Self-collection of
vaginal specimens for HPV testing has been shown to be
more effective at detecting CIN2þ than cervical cytology in
community-based randomized trials.23 The Ministry of
Health and Welfare in Taiwan began offering free self-
sampling HPV testing to women aged > 36 years who had
not received a Pap smear for 6 years, or handicaped women
aged > 30 years, but the response rate was unsatisfactory
by reminder letter (1.3% annually).1 The low response rate
was similar to our results, and we expected it to be higher
by mailing self-sampling kits directly instead of after
responding to our invitation letter. However, this expecta-
tion remains to be proven by a future field study.
Our previous study indicated that unawareness of the
importance of Pap smear, busyness, and shyness were theTable 5 Opinions about self-sampling HPV testing
(n Z 282).
Opinions n %
Simple & acceptable 256 90.8
No definite discomfort 248 87.9
Bleeding/lower abdominal pain/discharge 29 10.3
Willing to take the method again 246 87.2
Glad to recommend to other people 249 88.3
The method resolve the problem not attend
Pap smear screening for years
184 65.2
HPV Z human papillomavirus.
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women with newly diagnosed cervical cancer.24 Resaei
et al25 reported that educational intervention for cervical
cancer prevention by booklets, though not as substantial as
lectures, was significantly more effective as compared to
no manipulation.
Most respondent women found self-sampling HPV by mail
acceptable (90.5%), and self-sampling with our kit not un-
comfortable (87.2%), which ensure the feasibility of this
method in the general population. The results from the
knowledge questionnaire among Pap under-users in our
study exceeded our expectations. Although it was similar to
an open-book test, it impacted the knowledge and behavior
of these women toward cervical screening. Although the
response rate was unsatisfactory, the current study
changed those under-users who responded, because
58.5e73% ultimately accepted Pap smear or cervical biopsy
in the following 9 months after enrolment. The national
health database will allow us to determine whether the
current study also changed non-responders behavior toward
greater motivation for cervical screening. Television,
newspapers, and magazines are useful media methods for
delivering educational interventions.
In conclusion, our study indicated that under-screened
population are not easy to access, but that health bro-
chures increased receiver knowledge on cervical cancer
and HPV. Different approaches must be explored to improve
the coverage rate in populations with similar cultural
characteristics as Taiwan. Direct-mailed HPV kits to all
under-users instead of mailing kits on request might be a
reasonable alternative. A face-to-face educational inter-
vention project through volunteer obstetricians and gyne-
cologists serving as community cancer-prevention
advocates is currently underway.
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